Innate Pharma (IPHA) Receivables - Net (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Receivables - Net data on file, last reported at $14.7 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net fell 3.63% year-over-year to $14.7 million; the trailing twelve-month figure through Dec 2025 stood at $14.7 million (down 3.63% YoY), and the FY2025 full-year result was $14.7 million, down 3.63% from the prior year.
• Receivables - Net for Q4 2025 stood at $14.7 million, up from $5.6 million in the prior quarter.
• Across five years, Receivables - Net topped out at $71.1 million in Q4 2023 and bottomed at $5.6 million in Q2 2025.
• The 5-year median for Receivables - Net is $37.4 million (2024), against an average of $38.4 million.
• The widest annual swing landed in 2021, when Receivables - Net sank 99.66%; it then surged 153.92% in 2022.
• A 5-year view of Receivables - Net shows it stood at $21.1 million in 2021, then surged by 153.92% to $53.5 million in 2022, then surged by 32.94% to $71.1 million in 2023, then plunged by 78.52% to $15.3 million in 2024, then declined by 3.63% to $14.7 million in 2025.
• The last three Receivables - Net figures came in at $14.7 million (Q4 2025), $5.6 million (Q2 2025), and $15.3 million (Q4 2024), per Business Quant data.

Peer Comparison